Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Emerging Roles of SIRT1 in Cancer Drug Resistance.

Wang Z, Chen W.

Genes Cancer. 2013 Mar;4(3-4):82-90. doi: 10.1177/1947601912473826.

2.

Tumor microenvironment and cancer therapy resistance.

Sun Y.

Cancer Lett. 2015 Aug 10. pii: S0304-3835(15)00512-1. doi: 10.1016/j.canlet.2015.07.044. [Epub ahead of print]

PMID:
26272180
3.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
4.

Activating transcription factor 4 confers a multidrug resistance phenotype to gastric cancer cells through transactivation of SIRT1 expression.

Zhu H, Xia L, Zhang Y, Wang H, Xu W, Hu H, Wang J, Xin J, Gang Y, Sha S, Xu B, Fan D, Nie Y, Wu K.

PLoS One. 2012;7(2):e31431. doi: 10.1371/journal.pone.0031431. Epub 2012 Feb 17.

5.

MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.

Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M.

Prostate. 2010 Oct 1;70(14):1501-12. doi: 10.1002/pros.21185.

PMID:
20687223
6.

[Research advance on role of tumor microenvironment in mediating acquired drug resistance].

Ma XL, Xing H, Ma D.

Ai Zheng. 2007 Aug;26(8):923-6. Review. Chinese.

PMID:
17697561
7.

Sirtuin 1 regulates skeletal myoblast survival and enhances differentiation in the presence of resveratrol.

Saini A, Al-Shanti N, Sharples AP, Stewart CE.

Exp Physiol. 2012 Mar;97(3):400-18. doi: 10.1113/expphysiol.2011.061028. Epub 2011 Nov 28.

8.

New horizons in tumor microenvironment biology: challenges and opportunities.

Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, Hu G, Sun Y.

BMC Med. 2015 Mar 5;13:45. doi: 10.1186/s12916-015-0278-7. Review.

9.

Apoptosis and cancer stem cells: Implications for apoptosis targeted therapy.

Kruyt FA, Schuringa JJ.

Biochem Pharmacol. 2010 Aug 15;80(4):423-30. doi: 10.1016/j.bcp.2010.04.010. Epub 2010 Apr 13.

PMID:
20394737
10.

Drug resistance: challenges to effective therapy.

Shekhar MP.

Curr Cancer Drug Targets. 2011 Jun;11(5):613-23. Review.

PMID:
21486215
11.

SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.

Chen HC, Jeng YM, Yuan RH, Hsu HC, Chen YL.

Ann Surg Oncol. 2012 Jun;19(6):2011-9. doi: 10.1245/s10434-011-2159-4. Epub 2011 Dec 7.

PMID:
22146883
12.

Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.

Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N.

Cancer Sci. 2003 Jan;94(1):15-21. Review.

13.

Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.

Shapira A, Livney YD, Broxterman HJ, Assaraf YG.

Drug Resist Updat. 2011 Jun;14(3):150-63. doi: 10.1016/j.drup.2011.01.003. Epub 2011 Feb 16. Review.

PMID:
21330184
14.

Nicotinamide prohibits proliferation and enhances chemosensitivity of pancreatic cancer cells through deregulating SIRT1 and Ras/Akt pathways.

Zhang JG, Zhao G, Qin Q, Wang B, Liu L, Liu Y, Deng SC, Tian K, Wang CY.

Pancreatology. 2013 Mar-Apr;13(2):140-6. doi: 10.1016/j.pan.2013.01.001. Epub 2013 Jan 9.

PMID:
23561972
15.

Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.

Lefranc F, Rynkowski M, DeWitte O, Kiss R.

Adv Tech Stand Neurosurg. 2009;34:3-35. Review.

PMID:
19368079
16.

Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1.

Chu F, Chou PM, Zheng X, Mirkin BL, Rebbaa A.

Cancer Res. 2005 Nov 15;65(22):10183-7.

17.

CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer.

Hao JL, Cozzi PJ, Khatri A, Power CA, Li Y.

Curr Cancer Drug Targets. 2010 May;10(3):287-306. Review.

PMID:
20370680
18.

Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival.

Beier UH, Wang L, Bhatti TR, Liu Y, Han R, Ge G, Hancock WW.

Mol Cell Biol. 2011 Mar;31(5):1022-9. doi: 10.1128/MCB.01206-10. Epub 2011 Jan 3.

19.

Modulation of cell sensitivity to antitumor agents by targeting survival pathways.

Perego P, Cossa G, Zuco V, Zunino F.

Biochem Pharmacol. 2010 Nov 15;80(10):1459-65. doi: 10.1016/j.bcp.2010.07.030. Epub 2010 Aug 3.

PMID:
20688050
20.

Survivin mediates resistance to antiandrogen therapy in prostate cancer.

Zhang M, Latham DE, Delaney MA, Chakravarti A.

Oncogene. 2005 Apr 7;24(15):2474-82.

PMID:
15735703
Items per page

Supplemental Content

Write to the Help Desk